Francioli P B, Glauser M P
Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Antimicrob Agents Chemother. 1993 Feb;37(2):207-12. doi: 10.1128/AAC.37.2.207.
We have conducted experiments to determine if one daily injection of netilmicin (NET) would be synergistic with the broad-spectrum cephalosporin ceftriaxone (CRO) in the treatment of experimentally induced endocarditis. Rats with catheter-induced aortic vegetations were infected intravenously with 3 x 10(7) CFU of a beta-lactam-sensitive strain of Streptococcus sanguis or a beta-lactam-resistant strain of Streptococcus mitis. Treatment with the antibiotics alone (CRO, 10 mg/kg of body weight every 8 h; NET, 18 mg/kg every 24 h) or in combinations which had proved synergistic in in vitro time-kill curves was commenced 48 h postinfection and continued for 72 h. The results show that the combination was markedly effective against S. sanguis and moderately effective against S. mitis, while, with the protocol used here, the agents alone were not. The results suggest that CRO-NET should be an effective combination for treating streptococcal endocarditis in humans and may permit a shorter duration of treatment and once-a-day dosing to be used.
我们进行了实验,以确定每日一次注射奈替米星(NET)与广谱头孢菌素头孢曲松(CRO)联合使用,在治疗实验性诱导的心内膜炎时是否具有协同作用。将导管诱导形成主动脉赘生物的大鼠静脉注射3×10⁷CFU的β-内酰胺敏感的血链球菌菌株或β-内酰胺耐药的缓症链球菌菌株。感染后48小时开始单独使用抗生素治疗(CRO,每8小时10mg/kg体重;NET,每24小时18mg/kg),或使用在体外时间杀菌曲线中已证明具有协同作用的联合用药方案,并持续72小时。结果表明,联合用药对血链球菌具有显著疗效,对缓症链球菌具有中度疗效,而在此处使用的方案下,单独使用这些药物则无效。结果表明,CRO-NET联合用药应是治疗人类链球菌性心内膜炎的有效组合,并且可能允许使用更短的治疗疗程和每日一次给药。